(Q36214633)

12 August 2017

1 reference

title

Treatment of advanced ovarian cancer: 10 years of experience (English)

1 reference

12 August 2017

1 reference

1 reference

https://api.crossref.org/works/10.1093/OXFORDJOURNALS.ANNONC.A058056

14 October 2022

author name string

J. P. Neijt

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1606064

14 October 2022

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=1606064

14 October 2022

publication date

1 January 1992

1 reference

full work available at URL

12 August 2017

http://annonc.oxfordjournals.org/cgi/content/abstract/3/1/17

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1606064

https://api.elsevier.com/content/article/PII:S0923753419651100?httpAccept=text/xml

14 October 2022

1 reference

https://api.crossref.org/works/10.1093/OXFORDJOURNALS.ANNONC.A058056

https://api.elsevier.com/content/article/PII:S0923753419651100?httpAccept=text/plain

14 October 2022

1 reference

https://api.crossref.org/works/10.1093/OXFORDJOURNALS.ANNONC.A058056

http://academic.oup.com/annonc/article-pdf/3/1/17/387635/3-1-17.pdf

14 October 2022

file format

Portable Document Format

1 reference

https://api.crossref.org/works/10.1093/OXFORDJOURNALS.ANNONC.A058056

14 October 2022

1 reference

12 August 2017

3

1 reference

12 August 2017

17-27

1 reference

12 August 2017

1

1 reference

Cancer in the European community and its member states

12 August 2017

1

1 reference

https://api.crossref.org/works/10.1093/OXFORDJOURNALS.ANNONC.A058056

Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience

14 October 2022

2

1 reference

https://api.crossref.org/works/10.1093/OXFORDJOURNALS.ANNONC.A058056

A new histologic grading index in ovarian carcinoma

14 October 2022

4

1 reference

https://api.crossref.org/works/10.1093/OXFORDJOURNALS.ANNONC.A058056

Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma

14 October 2022

6

1 reference

https://api.crossref.org/works/10.1093/OXFORDJOURNALS.ANNONC.A058056

Controversial aspects of cytoreductive surgery in epithelial ovarian cancer

14 October 2022

7

1 reference

https://api.crossref.org/works/10.1093/OXFORDJOURNALS.ANNONC.A058056

Pelvic and para-aortic lymphadenectomy in cancer of the ovary

14 October 2022

8

1 reference

https://api.crossref.org/works/10.1093/OXFORDJOURNALS.ANNONC.A058056

Randomized trial comparing two combination chemotherapy regimens (CHAP-5 v CP) in advanced ovarian carcinoma

14 October 2022

10

1 reference

https://api.crossref.org/works/10.1093/OXFORDJOURNALS.ANNONC.A058056

A second look at second-look laparotomy

14 October 2022

13

1 reference

https://api.crossref.org/works/10.1093/OXFORDJOURNALS.ANNONC.A058056

Current status of systemic chemotherapy in the treatment of advanced ovarian cancer with emphasis on CHAP-5.

14 October 2022

14

1 reference

https://api.crossref.org/works/10.1093/OXFORDJOURNALS.ANNONC.A058056

Rewiew of ovarian cancer at the University of Texas Systems Cancer Center, M.D. Anderson Hospital and Tumor Institute

14 October 2022

15

1 reference

https://api.crossref.org/works/10.1093/OXFORDJOURNALS.ANNONC.A058056

High-dose cisplatin in hypertonic saline in refractory ovarian cancer

14 October 2022

16

1 reference

https://api.crossref.org/works/10.1093/OXFORDJOURNALS.ANNONC.A058056

A prospective randomized trial comparing high-dose cisplatin with low-dose cisplatin and chlorambucil in advanced ovarian carcinoma

14 October 2022

17

1 reference

https://api.crossref.org/works/10.1093/OXFORDJOURNALS.ANNONC.A058056

High dose cisplatin compared with high dose cyclophosphamide in the management of advanced epithelial ovarian cancer (FIGO stages III and IV): report from the North Thames Cooperative Group.

14 October 2022

18

1 reference

https://api.crossref.org/works/10.1093/OXFORDJOURNALS.ANNONC.A058056

Randomized trial in advanced ovarian cancer comparing cisplatin and carboplatin

14 October 2022

22

1 reference

https://api.crossref.org/works/10.1093/OXFORDJOURNALS.ANNONC.A058056

Cisplatin/carboplatin cross-resistance in ovarian cancer

14 October 2022

23

1 reference

https://api.crossref.org/works/10.1093/OXFORDJOURNALS.ANNONC.A058056

Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms

14 October 2022

24

1 reference

https://api.crossref.org/works/10.1093/OXFORDJOURNALS.ANNONC.A058056

Old drugs revisited, new drugs, and experimental approaches in ovarian cancer therapy

14 October 2022

26

1 reference

https://api.crossref.org/works/10.1093/OXFORDJOURNALS.ANNONC.A058056

Phase II study of low-dose mitomycin in patients with ovarian cancer previously treated with chemotherapy

14 October 2022

29

1 reference

https://api.crossref.org/works/10.1093/OXFORDJOURNALS.ANNONC.A058056

Ifosfamide given as a 24-h infusion with mesna in patients with recurrent ovarian cancer: preliminary results.

14 October 2022

32

1 reference

https://api.crossref.org/works/10.1093/OXFORDJOURNALS.ANNONC.A058056

Phase II trial of ifosfamide and mesna in advanced ovarian carcinoma: a Gynecologic Oncology Group Study

14 October 2022

33

1 reference

https://api.crossref.org/works/10.1093/OXFORDJOURNALS.ANNONC.A058056

Responsiveness of patients with advanced ovarian carcinoma to tamoxifen. A Gynecologic Oncology Group study of second-line therapy in 105 patients

14 October 2022

34

1 reference

https://api.crossref.org/works/10.1093/OXFORDJOURNALS.ANNONC.A058056

Advanced ovarian carcinoma: A prospective and randomized clinical trial of cyclophosphamide versus combination cytotoxic chemotherapy (Hexa-CAF)

14 October 2022

39

1 reference

https://api.crossref.org/works/10.1093/OXFORDJOURNALS.ANNONC.A058056

A randomized study of cyclophosphamide and cis-platinum with or without doxorubicin in advanced ovarian carcinoma

14 October 2022

42

1 reference

https://api.crossref.org/works/10.1093/OXFORDJOURNALS.ANNONC.A058056

A randomized trial comparing cisplatin plus cyclophosphamide versus cisplatin, doxorubicin, and cyclophosphamide in advanced ovarian cancer

14 October 2022

43

1 reference

https://api.crossref.org/works/10.1093/OXFORDJOURNALS.ANNONC.A058056

Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma: a Gynecologic Oncology Group Study

14 October 2022

44

1 reference

https://api.crossref.org/works/10.1093/OXFORDJOURNALS.ANNONC.A058056

Current status of chemotherapy for ovarian carcinoma

14 October 2022

46

1 reference

https://api.crossref.org/works/10.1093/OXFORDJOURNALS.ANNONC.A058056

Cyclophosphamide-cisplatin versus cyclophosphamide-carboplatin in stage III-IV ovarian carcinoma: a comparison of equally myelosuppressive regimens

14 October 2022

49

1 reference

https://api.crossref.org/works/10.1093/OXFORDJOURNALS.ANNONC.A058056

Carboplatin in combination therapy for ovarian cancer

14 October 2022

52

1 reference

https://api.crossref.org/works/10.1093/OXFORDJOURNALS.ANNONC.A058056

Ovarian cancer treatment: time for some hard thinking

14 October 2022

55

1 reference

https://api.crossref.org/works/10.1093/OXFORDJOURNALS.ANNONC.A058056

Consolidation with intraperitoneal cisplatin in first-line therapy of advanced ovarian cancer

14 October 2022

57

1 reference

https://api.crossref.org/works/10.1093/OXFORDJOURNALS.ANNONC.A058056

Intraperitoneal therapy in ovarian cancer: time's up

14 October 2022

58

1 reference

https://api.crossref.org/works/10.1093/OXFORDJOURNALS.ANNONC.A058056

Intraperitoneal therapy in ovarian cancer: time's not up

14 October 2022

59

1 reference

https://api.crossref.org/works/10.1093/OXFORDJOURNALS.ANNONC.A058056

Intraperitoneal therapy in ovarian cancer: time's not up

14 October 2022

60

1 reference

https://api.crossref.org/works/10.1093/OXFORDJOURNALS.ANNONC.A058056

Long-term survival in ovarian cancer. Mature data from The Netherlands Joint Study Group for Ovarian Cancer

14 October 2022

61

1 reference

https://api.crossref.org/works/10.1093/OXFORDJOURNALS.ANNONC.A058056

Long-term results of a cisplatin-containing combination chemotherapy regimen for the treatment of advanced ovarian carcinoma

14 October 2022

62

1 reference

https://api.crossref.org/works/10.1093/OXFORDJOURNALS.ANNONC.A058056

Advanced ovarian cancer: long-term results of treatment with intensive cisplatin-based chemotherapy of brief duration

14 October 2022

63

1 reference

https://api.crossref.org/works/10.1093/OXFORDJOURNALS.ANNONC.A058056

Ten-year follow-up of patients receiving cisplatin, doxorubicin, and cyclophosphamide chemotherapy for advanced epithelial ovarian carcinoma

14 October 2022

64

1 reference

https://api.crossref.org/works/10.1093/OXFORDJOURNALS.ANNONC.A058056

Long-term follow-up of patients with advanced ovarian carcinoma treated with debulking surgery and chemotherapy consisting of cisplatin, doxorubicin, and cyclophosphamide. Gynecologic Oncology Group of the Comprehensive Cancer Center

14 October 2022

65

1 reference

https://api.crossref.org/works/10.1093/OXFORDJOURNALS.ANNONC.A058056

Long-term survival after chemotherapy with cisplatinum, adriamycin and cyclophosphamide for carcinoma of the ovary

14 October 2022

66

1 reference

https://api.crossref.org/works/10.1093/OXFORDJOURNALS.ANNONC.A058056

Speed of response to platinum-based chemotherapy: implications for the management of epithelial ovarian cancer

14 October 2022

68

1 reference

https://api.crossref.org/works/10.1093/OXFORDJOURNALS.ANNONC.A058056

CA-125 monitoring in the management of ovarian cancer

14 October 2022

69

1 reference

https://api.crossref.org/works/10.1093/OXFORDJOURNALS.ANNONC.A058056

Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin

14 October 2022

72

1 reference

https://api.crossref.org/works/10.1093/OXFORDJOURNALS.ANNONC.A058056

Dose intensity analysis of chemotherapy regimens in ovarian carcinoma

14 October 2022

73

1 reference

https://api.crossref.org/works/10.1093/OXFORDJOURNALS.ANNONC.A058056

High-dose melphalan and autologous bone marrow support for treatment of ovarian carcinoma with positive second-look operation

14 October 2022

77

1 reference

https://api.crossref.org/works/10.1093/OXFORDJOURNALS.ANNONC.A058056

High-dose chemotherapy with autologous bone marrow transplantation in patients with refractory ovarian cancer

14 October 2022

79

1 reference

https://api.crossref.org/works/10.1093/OXFORDJOURNALS.ANNONC.A058056

High-dose carboplatin in refractory ovarian cancer patients.

14 October 2022

81

1 reference

https://api.crossref.org/works/10.1093/OXFORDJOURNALS.ANNONC.A058056

Cisplatin combined with carboplatin: a new way of intensification of platinum dose in the treatment of advanced ovarian cancer. Belgian Study Group for Ovarian Carcinoma

14 October 2022

82

1 reference

https://api.crossref.org/works/10.1093/OXFORDJOURNALS.ANNONC.A058056

Resistance to alkylating agents and cisplatin: insights from ovarian carcinoma model systems

14 October 2022

84

1 reference

https://api.crossref.org/works/10.1093/OXFORDJOURNALS.ANNONC.A058056

14 October 2022

Identifiers

1 reference

12 August 2017

1 reference